You are here: Industry Insights > AbbVie

News List

AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate europeanpharmaceuticalreview
April 25, 2017
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A) achieved sustained virologic response...
FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab drugs.com
April 06, 2017
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque ps
FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab drugs
March 31, 2017
AbbVie (NYSE: ABBV)announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque pso
AbbVie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir pharmaasia
March 27, 2017
AbbVie to prioritize review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir for the treatment of major genotypes of chronic Hepatitis C
UK High Court rules against AbbVie’s Humira patents pharmafile
March 07, 2017
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and psoriatic, were invalid. The case was ...
AbbVie receives CHMP positive opinion for Hep C tablet combination europeanpharmaceuticalreview
March 03, 2017
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax...
AbbVie’s VIEKIRAX + EXVIERA receives positive opinion for eight-week treatment of GT1b HCV pharmaceutical-technology
March 01, 2017
AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets).
AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® + EXVIERA® February 28, 2017
AbbVie announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for a shorter,
NICE does not recommend AbbVie’s leukaemia drug europeanpharmaceuticalreview
February 17, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend venetoclax (Venclyxto, AbbVie) within its marketing authorisation for treating chronic lymphocytic leukaemia.
US FDA approves AbbVie’s Imbruvica to treat marginal zone lymphoma pharmaceutical-technology
January 24, 2017
The US Food and Drug Administration (FDA) has approved AbbVie’s Imbruvica (ibrutinib) for the treatment of patients with relapsed / refractory (R/R) marginal zone lymphoma (MZL).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page